-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
-
- Our Pipeline Development
-
Nu.Q® Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
-
Capture-Seq™
We have developed Capture-Seq™, a novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples.
Volition Expands Contract with Fujifilm to Include the Nu.Q® Vet Test for Cats
- Share
- Tweet
- Share on Facebook
- Share
Expansion extends potential use of Nu.Q® technology to Japan’s almost nine million cats
Volition expects Nu.Q® Vet Feline Test to be the world’s first simple, affordable blood-based liquid biopsy test for feline cancer
Henderson, Nevada, November 16, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces the expansion of its supply agreement with Fujifilm Vet Systems Co. Ltd (“Fujifilm”) in Japan, allowing the development and use of the Nu.Q® Vet Feline Test.
Junichi Makino, President and Representative Director at Fujifilm Vet Systems, said:
“There are almost nine million cats in Japan1 and so we are excited to extend the potential use of the Nu.Q® technology to our feline clients. Feline oncology lacks tumor biomarkers and so cancer in cats has been notoriously difficult to diagnose early.
“Since our launch of the Nu.Q® Vet Canine Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians, so much so that earlier this year we introduced the automated test to enable a more rapid turnaround and high throughput to meet increasing demand.
“The paper reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats2, the most common cancer in the species3, is incredibly encouraging and we look forward to completing a further study with veterinary oncologists in Japan.”
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, added:
“Given Fujifilm Vet Systems is a leading provider of diagnostic tests in this large market, the expansion to include feline use presents an exciting revenue opportunity for Volition.
“One in five cats will be diagnosed with cancer in their lifetimes4 and earlier detection can improve outcomes.
“The ownership of cats and dogs has been increasing across the globe, including in emerging economies, with estimates of over a billion cats and dogs worldwide5.
“Our mission is to make cancer screening a routine part of every pet’s annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.
“This breakthrough marks the development of what we expect to be the world’s first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.
“We look forward to completing product development and launching the Nu.Q® Vet Feline Test on the Immunodiagnostic Systems (IDS) i10® automated analyzer platform.”
- Cat Statistics in Japan 2026 | 40+ Verified Facts | Cat Statistics 2026
- Canale et al
- Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen’s Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.
- Cat Cancer Statistics
- Global Pet Statistics
About Fujifilm Vet Systems
Fujifilm Vet Systems is a subsidiary of Fujifilm Holdings Corporation, listed on the Tokyo Stock Exchange under ticker 4901.
Fujifilm Vet Systems provides testing services centered on health checkups to veterinary medical facilities nationwide with relationships throughout the estimated 11,000 veterinary medical facilities in Japan. Fujifilm Vet Systems can also handle specialized examinations that cannot be performed at veterinary hospitals. In addition, they have established central reference laboratories at 10 bases in Japan and have led the market by providing services that quickly report test results by utilizing their testing and specimen collection network.
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields